In a recent study Maithel et al. prospectively selected 95 patients who underwent pancreaticoduodenectomy for pancreatic adenocarcinoma to perform immunohistochemistry for ERCC1 expression; seventy-three out of 95 patients (77%) received adjuvant chemotherapy ± radiation after resection. This evidence concerns the gene ERCC1 and pancreatic adenocarcinoma.